Compare IHRT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | ADCT |
|---|---|---|
| Founded | 1974 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.2M | 483.1M |
| IPO Year | 2019 | 2020 |
| Metric | IHRT | ADCT |
|---|---|---|
| Price | $3.92 | $3.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.50 | ★ $7.60 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 02-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,856,033,000.00 | $75,209,000.00 |
| Revenue This Year | $1.96 | $10.36 |
| Revenue Next Year | $5.62 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.39 | ★ 6.35 |
| 52 Week Low | $0.95 | $1.05 |
| 52 Week High | $5.44 | $4.80 |
| Indicator | IHRT | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 47.55 |
| Support Level | $4.31 | $3.38 |
| Resistance Level | $4.28 | $3.66 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 4.13 | 45.39 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).